minimal Common Oncology Data Elements (mCODE) Implementation Guide
3.0.0 - STU3 Release United States of America flag

minimal Common Oncology Data Elements (mCODE) Implementation Guide, published by HL7 International / Clinical Interoperability Council. This is not an authorized publication; it is the continuous build for version 3.0.0). This version is based on the current content of https://github.com/HL7/fhir-mCODE-ig/ and changes regularly. See the Directory of published versions

: cancer-related-medication-admin-doxorubicin-jenny-m - JSON Representation

Raw json | Download


{
  "resourceType" : "MedicationAdministration",
  "id" : "cancer-related-medication-admin-doxorubicin-jenny-m",
  "meta" : {
    "profile" : [
      "http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-cancer-related-medication-administration"
    ]
  },
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative: MedicationAdministration</b><a name=\"cancer-related-medication-admin-doxorubicin-jenny-m\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource MedicationAdministration &quot;cancer-related-medication-admin-doxorubicin-jenny-m&quot; </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-mcode-cancer-related-medication-administration.html\">Cancer-Related Medication Administration Profile</a></p></div><p><b>status</b>: completed</p><p><b>category</b>: Outpatient <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-medicationrequest-category.html\">MedicationRequest Category Codes</a>#outpatient)</span></p><p><b>medication</b>: doxorubicin hydrochloride 20 MG per 10 ML Injection <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-v3-rxNorm.html\">RxNorm</a>#1790099)</span></p><p><b>subject</b>: <a href=\"Patient-cancer-patient-jenny-m.html\">Patient/cancer-patient-jenny-m</a> &quot; M&quot;</p><p><b>effective</b>: 2018-04-22</p><h3>Performers</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Actor</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"Practitioner-us-core-practitioner-nancy-oncology-nurse.html\">Practitioner/us-core-practitioner-nancy-oncology-nurse</a> &quot; NURSE&quot;</td></tr></table><p><b>reasonReference</b>: <a href=\"Condition-primary-cancer-condition-jenny-m.html\">Condition/primary-cancer-condition-jenny-m</a></p><p><b>request</b>: <a href=\"MedicationRequest-cancer-related-medication-request-doxorubicin-jenny-m.html\">MedicationRequest/cancer-related-medication-request-doxorubicin-jenny-m</a></p><p><b>note</b>: doxorubicin (60 mg/m² IV), 105.96 mg in 50 ml 0.9% normal saline administered by continuous infusion. Patient tolerated infusion without side effects. (By Practitioner/us-core-practitioner-nancy-oncology-nurse @2018-04-22)</p><h3>Dosages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Route</b></td><td><b>Dose</b></td></tr><tr><td style=\"display: none\">*</td><td>Intravenous route (qualifier value) <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"https://browser.ihtsdotools.org/\">SNOMED CT</a>#47625008)</span></td><td>105.96 mg<span style=\"background: LightGoldenRodYellow\"> (Details: UCUM code mg = 'mg')</span></td></tr></table></div>"
  },
  "status" : "completed",
  "category" : {
    "coding" : [
      {
        "system" : "http://terminology.hl7.org/CodeSystem/medicationrequest-category",
        "code" : "outpatient"
      }
    ]
  },
  "medicationCodeableConcept" : {
    "coding" : [
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "code" : "1790099",
        "display" : "doxorubicin hydrochloride 20 MG per 10 ML Injection"
      }
    ]
  },
  "subject" : {
    "reference" : "Patient/cancer-patient-jenny-m"
  },
  "effectiveDateTime" : "2018-04-22",
  "performer" : [
    {
      "actor" : {
        "reference" : "Practitioner/us-core-practitioner-nancy-oncology-nurse"
      }
    }
  ],
  "reasonReference" : [
    {
      "reference" : "Condition/primary-cancer-condition-jenny-m"
    }
  ],
  "request" : {
    "reference" : "MedicationRequest/cancer-related-medication-request-doxorubicin-jenny-m"
  },
  "note" : [
    {
      "authorReference" : {
        "reference" : "Practitioner/us-core-practitioner-nancy-oncology-nurse"
      },
      "time" : "2018-04-22",
      "text" : "doxorubicin (60 mg/m² IV), 105.96 mg in 50 ml 0.9% normal saline administered by continuous infusion. Patient tolerated infusion without side effects."
    }
  ],
  "dosage" : {
    "route" : {
      "coding" : [
        {
          "system" : "http://snomed.info/sct",
          "code" : "47625008",
          "display" : "Intravenous route (qualifier value)"
        }
      ]
    },
    "dose" : {
      "value" : 105.96,
      "unit" : "mg",
      "system" : "http://unitsofmeasure.org",
      "code" : "mg"
    }
  }
}